| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
-SEC Filing
HC Wainwright & Co. analyst Ed Arce upgrades Synlogic (NASDAQ:SYBX) from Sell to Neutral.
Synlogic (NASDAQ:SYBX) reported quarterly losses of $(1.71) per share which missed the analyst consensus estimate of $(0.97) by...
Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious disease...